Gossamer Bio

Gossamer Bio ROA

The Return on Assets (ROA) of Gossamer Bio (GOSS) as of Oct 4, 2026 is -98.91 %. In the previous year, Return on Assets (ROA) was -17.93 % — a change of 451.68% (lower).

ROA

-98.91 %

YoY

451.68%

Last updated:

In 2026, Gossamer Bio's return on assets (ROA) was -98.91 %, a 451.68% increase from the -17.93 % ROA in the previous year.

The Gossamer Bio ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-61.39 USD
Jan 1, 2019
-42.39 USD
Jan 1, 2020
-45.11 USD
Jan 1, 2021
-68.09 USD
Jan 1, 2022
-84.19 USD
Jan 1, 2023
-57.65 USD
Jan 1, 2024
-17.93 USD
Jan 1, 2025
-98.91 USD
The Gossamer Bio ROA history
YEARROAYoY
-98.91 %+451.68%
-17.93 %-68.90%
-57.65 %-31.53%
-84.19 %+23.64%
-68.09 %+50.93%
-45.11 %+6.44%
-42.39 %-30.95%
-61.39 %-95.97%
-1,521.57 %+999.93%
-138.33 %—
Access this data via the Eulerpool API

Gossamer Bio Stock analysis

What does Gossamer Bio do? The company Gossamer Bio Inc. was founded in 2015 by Faheem Hasnain and Sheila Gujrathi. The founders had previously worked at various biotechnology companies and now wanted to start their own company to develop innovative products in the field of immunology. Gossamer Bio is headquartered in San Diego, California and currently employs around 200 people. The company specializes in researching and developing therapeutics for a wide range of diseases, including respiratory diseases, cancer, immunological disorders, and infections. Gossamer Bio's business model is based on identifying promising new drug candidates and subsequently developing therapeutics that have the potential to improve patients' lives. Key pillars of the business model include partnerships with established companies and investors, as well as the rapid and efficient conduct of clinical trials. Gossamer Bio's portfolio includes various pipeline programs in different stages of development. An important focus is on the development of new drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A promising drug candidate in this area is GB001, an inhalation medication that aims to reduce inflammation in the airways. Another important program of Gossamer Bio is the development of therapeutics for the treatment of cancer. The company focuses on the development of drugs that target the body's immune system to specifically fight tumor cells. A promising drug candidate in this area is GB1275, an antibody that specifically targets a protein overexpressed by some types of cancer. In addition to these two focus areas, Gossamer Bio also has programs in the development of therapeutics for the treatment of immunological disorders such as inflammatory bowel disease and rheumatoid arthritis, as well as for the treatment of infections such as COVID-19. Overall, Gossamer Bio has a wide range of promising drug candidates that have the potential to revolutionize the field of immunology and disease management. The company is well positioned to make significant progress in the development of new therapeutics in the coming years and improve the lives of millions of patients worldwide. Gossamer Bio is one of the most popular companies on Eulerpool.

ROA Details

Understanding Gossamer Bio's Return on Assets (ROA)

Gossamer Bio's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Gossamer Bio's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Gossamer Bio's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Gossamer Bio’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Gossamer Bio stock

Return on Assets (ROA) of Gossamer Bio is -98.91 % in 2026.

Return on Assets (ROA) of Gossamer Bio changed from -17.93 % to -98.91 %, representing a 451.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Gossamer Bio since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Gossamer Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Gossamer Bio

All Key Metrics — Gossamer Bio